Patients who take the medication but make no changes to their eating habits typically lose less weight and are more likely to regain it
CrossRef Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events Daqiu Chen, Zixun Wang, Zhanxiong Xie, Yixing Chen, Shunxiang Luo, Shanghua Xu Frontiers in Pharmacology.2026;[Epub] CrossRef Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study Ying Wang, Hongning Li, Zhongyuan Zhang, Xiaocen Kong, Huiqin Li, Weichun Qian, Jianhua Ma Frontiers in Endocrinology.2026;[Epub] CrossRef Inflammation-autonomic cross talk contributes to left ventricular diastolic dysfunction in type 2 diabetes: a rationale for neuromodulation Nuwani Wijesooriya, Senali Silva, Dulani Kottahachchi, Nadisha Badanasinghe, Dinu S
Blog Author: Dr
Is tirzepatide well studied